Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Profitability ⢠Deleveraging Progress ⢠Intangible Exposure BMY delivers strong margins, cash flow, and improving leverage, but substantial debt and intangible-asset exposure warrant continued balance-sheet monitoring.
Price Behavior
Key Price Behavior Insights: ⢠Bearish Momentum ⢠Support Test ⢠Oversold RSI Support Level: $63.60â$63.80 Resistance Level: $66.80â$67.00 BMY has turned bearish over the last month, falling 6.5% to $63.64 below its $66.11 average; watch $63.60â$63.80 support for a rebound, while a break lower raises downside risk.
Sentiment & News
Key News Insights: ⢠Growth Portfolio ⢠Pipeline Progress ⢠Patent Headwinds Bristol Myers Squibb's growth portfolio, pipeline progress and raised guidance support its transition outlook, though legacy-product declines and patent risks continue to pressure shares.
AI Summary
BMY is a discounted portfolio-transition investmentânot a simple value playâwhere 15% growth in brands now comprising ~60% of revenue and strong cash generation can offset legacy erosion only if execution persists before Eliquis patent and pricing pressures intensify; investors should favor the shares only with evidence of sustained growth-brand scale-up and monitor the $63.6 support level closely.
Description
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, licenses, manufactures and markets medicines across oncology, hematology, cardiovascular, immunology, fibrosis, neuroscience and infectious disease. Its commercial portfolio includes oral and biologic therapies for cancer, cardiovascular and immune-mediated conditions, with widely used products such as Eliquis and Opdivo, and it sells through wholesalers, pharmacies, hospitals and government channels. Founded in 1887, the company is headquartered in New York, New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 9 | Feb 16 | BMY | Bristol-Myers Squibb Company | Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days. | Closed | -0.1% |
| Dec 23 | Dec 30 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case. | Closed | -0.1% |
| Dec 4 | Dec 11 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb shows compelling near-term upside with strong Q3 revenue and raised guidance, notable clinical/regulatory catalysts (FDA Fast Track, Phase 3 trials), substantial debt reduction, and technical breakout signaling positive momentum. | Closed | -1.4% |